The Coca-Cola Company and Bacardi Limited Announce Plans to Debut BACARDÍ & Coca-Cola Ready-To-Drink Cocktail
The Coca-Cola Company and Bacardi Limited today announced an agreement to debut BACARDÍ rum and Coca-Cola as a ready-to-drink (RTD) pre-mixed cocktail.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917932386/en/
BACARDÍ rum and Coca-Cola ready-to-drink (RTD) pre-mixed cocktail (Photo: Business Wire)
BACARDÍ Mixed with Coca-Cola RTD will be available in several markets around the world, with the initial launch planned for select European markets and Mexico in 2025.
“We are continuing to develop our portfolio as a total beverage company, including in the growing alcohol ready-to-drink market,” said James Quincey, Chairman and CEO of The Coca-Cola Company. “This new relationship with Bacardi Limited supports our strategic expansion, and we look forward to the introduction of BACARDÍ Mixed with Coca-Cola next year.”
“We are excited to bring together two iconic brands so that consumers may enjoy one of the most world’s most popular cocktails – first invented generations ago with BACARDÍ rum and Coca-Cola – in a high-quality, convenient format,” said Mahesh Madhavan, CEO of Bacardi Limited. “Through this relationship, we will expand our reach and accessibility so that even more consumers of legal drinking age can enjoy this classic BACARDÍ rum and Coca-Cola cocktail.”
BACARDÍ Mixed with Coca-Cola RTD packaging will feature two of the world’s most recognizable global trademarks. Family-owned Bacardi was first established in 1862 in Cuba before moving to Bermuda, while Coca-Cola debuted in 1886 in Atlanta.
This is not the first time the two brands have come together. In 1900, the Cuba Libre cocktail was invented using BACARDÍ rum, Coca-Cola and lime at the American Bar in Havana. The combination of the most-awarded rum and the world’s most popular soft drink remains among the top bar calls globally.
Cans will include clear responsibility symbols stating that the drink is to be enjoyed only by consumers of legal drinking age. BACARDÍ Mixed with Coca-Cola RTD will adhere to responsible marketing practices held by The Coca-Cola Company and Bacardi Limited.
The global benchmark for alcohol beverage volume (ABV) is 5% but will vary depending on the market.
About The Coca-Cola Company
The Coca-Cola Company (NYSE: KO) is a total beverage company with products sold in more than 200 countries and territories. Our company’s purpose is to refresh the world and make a difference. We sell multiple billion-dollar brands across several beverage categories worldwide. Our portfolio of sparkling soft drink brands includes Coca-Cola, Sprite and Fanta. Our hydration, sports, coffee and tea brands include Dasani, smartwater, vitaminwater, Topo Chico, BODYARMOR, Powerade, Costa, Georgia, Gold Peak and Ayataka. Our nutrition, juice, dairy and plant-based beverage brands include Minute Maid, Simply, innocent, Del Valle, fairlife and AdeS. We’re constantly transforming our portfolio, from reducing sugar in our drinks to bringing innovative new products to market. We seek to positively impact people’s lives, communities and the planet through water replenishment, packaging recycling, sustainable sourcing practices and carbon emissions reductions across our value chain. Together with our bottling partners, we employ more than 700,000 people, helping bring economic opportunity to local communities worldwide. Learn more at www.coca-colacompany.com and follow us on Instagram, Facebook and LinkedIn.
About Bacardi Limited
Bacardi Limited, the world’s largest privately held international spirits company, produces, markets, and distributes spirits and wines. The Bacardi Limited portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, PATRÓN® tequila, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, D’USSÉ® Cognac, ANGEL’S ENVY® American straight whiskey, and ST-GERMAIN® elderflower liqueur. Founded more than 162 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 11 countries and territories, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on LinkedIn or Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917932386/en/
Contacts
The Coca-Cola Company:
The Coca-Cola Company:
Investors and Analysts: Robin Halpern, koinvestorrelations@coca-cola.com
Media: Scott Leith, sleith@coca-cola.comBacardi Limited:
Media: Jessica Merz, jmerz@bacardi.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coulson Aviation Announces Launch of Boeing 767 VLAT Program22.12.2025 14:03:00 CET | Press release
Advancing the Next Generation of High-Capacity Aerial Firefighting Coulson Aviation USA has announced the launch of its Boeing 767 Very Large Airtanker (VLAT) program, marking a significant advancement in the evolution of aerial firefighting capability. The program is intended to provide a sustainable replacement for legacy VLAT platforms nearing the end of their operational service life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222917730/en/ A cross-sectional view of Coulson Aviation’s Boeing 767 Very Large Airtanker (VLAT) illustrates the integration of the RADS retardant delivery system and the next generation of high-capacity, sustainable aerial firefighting design. The recent grounding of the MD11 and DC10 fleets has highlighted a structural challenge for firefighting agencies worldwide. As older widebody aircraft are retired, the industry faces a significant reduction in high-capacity, large-scale retardant de
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom